PURPOSE: Our purpose was to evaluate the effect of Erlotinib on the airway remodeling and airway inflammation in brown-Norway rats (BNR) induced after repeated ovalbumin challenge in BNR.
METHODS: Eighteen BNR were equally divided into three groups. Each group I and II BNR was sensitized by ovalbumin. Fifteen days later, the animals were challenged by ovalbumin for 6 times with 3 days interval in between. Erlotinib (1.5mg/kg/day) was given orally daily for the group I animals and only vehicle was given orally for the group II and group III animals. Group III breathe aerosolized saline under the same conditions as group II animals. After ovalbumin provocation, the animals were anesthetized. Lung tissues were stained with haematoxylin and eosin, Masson’ s trichrome, smooth muscle actin, and von Willebrand factor for microscopic examination.
RESULTS: Our results showed that group II had more severe lung inflammation than the other 2 groups. The airway inflammation, area of collagen deposition surrounding the airways, the mean thickness of the smooth muscle layer surrounding the airways, the mean number of the blood vessels surrounding the airways were lowest in the control group compared to the other 2 groups and significantly lower in the OA-Erlotinib group compared to the OA-saline group. The mean fold change of the mean area of the airway collagen deposition surrounding the airways relative to the control group was 1.7-fold in the OA- Erlotinib group and 3.2-fold in OA-saline group.
CONCLUSION: Erlotinib is effective in preventing airway remodeling and airway inflammation in BNR after repeated ovalbumin challenge.
CLINICAL IMPLICATIONS: Erlotinib may be effective in preventing airway remodeling and airway inflammation in asthma.
DISCLOSURE: Ching-Chi Lin, No Financial Disclosure Information; No Product/Research Disclosure Information